The European Medicines Agency (EMA) announced on March 24, 2017 that it was recommending the suspension of approved drugs and delaying the approval of drugs under review for which bioequivalence studies were conducted by Micro Therapeutic Research Labs. The suspension is because the agency has determined that the bioequivalence data produced by Micro Therapeutic Research Labs is unreliable.